Last updated
    Cencora
    Pharmaceutical distribution and healthcare solutions

    Cencora

    United States flagUnited States

    "Creating healthier futures"

    Founded January 1, 2001 Chesterbrook, Pennsylvania, United States CEO: Steven H. Collis
    Community

    About

    Cencora operates as one of the three dominant pharmaceutical wholesalers in the United States, managing the complex logistics that move medications from manufacturers to hospitals and pharmacies. The company traces its modern corporate origins to January 1, 2001, when AmeriSource Pharmaceutical Group merged with Bergen Brunswig to form AmerisourceBergen. In June 2023, the organization dropped the legacy name for Cencora to reflect a strategic pivot toward broader healthcare solutions beyond traditional drug distribution.

    Headquartered in Chesterbrook, Pennsylvania, the firm employs over 51,000 people globally who work to ensure medication availability across retail chains, long-term care facilities, and specialized clinics. Steven H. Collis has led the company as Chairman and CEO since 2009, overseeing expansions into specialty pharmacy services and veterinary medicine through its Covetrus division. While consumers rarely see the brand on their prescriptions, Cencora supplies major retailers like Walgreens and handles billions of doses annually.

    Products & Sub-brands

    AmerisourceBergen Specialty GroupConvaTecCovetrusGeneric pharmaceuticalsOver-the-counter products

    Frequently Asked Questions

    Who owns Cencora?
    Cencora is a publicly traded company listed on the New York Stock Exchange under the ticker symbol COR, owned by institutional investors and individual shareholders.
    Who is the CEO of Cencora?
    Steven H. Collis serves as the Chairman and Chief Executive Officer, having led the company since 2009 through its rebranding in 2023.
    Is Cencora still in business?
    Yes, Cencora remains an active global leader in pharmaceutical distribution and continues to expand its healthcare solutions portfolio.
    What is Cencora worth?
    As of mid-2026, the company trades around $318 per share, with analysts setting price targets near $330 following strong quarterly earnings.
    Does Cencora own Covetrus?
    Cencora previously acquired Covetrus to enter the animal health market, but announced plans in early 2026 to sell MWI Animal Health to Covetrus while maintaining a partnership.

    Keywords

    pharmaceutical wholesalerdrug distributionAmerisourceBergenspecialty pharmacyanimal healthhealthcare supply chainCovetrusSteven H. Collis

    Sources

    Company Info

    Founded
    January 1, 2001
    CEO
    Steven H. Collis
    Headquarters
    Chesterbrook, Pennsylvania, United States
    Industry
    Pharmaceutical distribution and healthcare solutions
    Parent Company
    Publicly traded (NYSE: COR)
    Employees
    51000
    Rebranded
    June 2023
    Stock Ticker
    COR
    Exchange
    New York Stock Exchange
    CEO Since
    2009
    Key Subsidiary
    Covetrus

    Official Website

    www.cencora.com/

    Join the community

    fans discussing